Novanta is trading 9.64% up at $185.01 in pre-market, with no clearly dated August 18, 2026 company announcement or reliable report directly explaining the jump.
- Recent coverage highlights strong second-quarter results, raised 2026 revenue guidance, and the Riverpoint Medical acquisition; these developments were reported earlier in August.
- Broader pre-market sentiment is weaker, with the Nasdaq Composite down 1.07% and S&P 500 down 0.42%.
- Trading volume and activity level were unavailable.